139 related articles for article (PubMed ID: 36734062)
41. PAR2 deficiency tunes inflammatory microenvironment to magnify STING signalling for mitigating cancer metastasis via anionic CRISPR/Cas9 nanoparticles.
Fu X; Li J; Wu Y; Mao C; Jiang Y
J Control Release; 2023 Nov; 363():733-746. PubMed ID: 37827223
[TBL] [Abstract][Full Text] [Related]
42. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
44. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
[TBL] [Abstract][Full Text] [Related]
45. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
46. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
Tao Y; Yi K; Hu H; Shao D; Li M
J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
[TBL] [Abstract][Full Text] [Related]
47. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
48. Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
Song N; Chu Y; Tang J; Yang D
Chembiochem; 2023 Aug; 24(16):e202300180. PubMed ID: 37183575
[TBL] [Abstract][Full Text] [Related]
49. Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing.
Xiu K; Saunders L; Wen L; Ruan J; Dong R; Song J; Yang D; Zhang J; Xu J; Chen YE; Ma PX
Cells; 2022 Dec; 12(1):. PubMed ID: 36611948
[TBL] [Abstract][Full Text] [Related]
50. Smart arginine-equipped polycationic nanoparticles for p/CRISPR delivery into cells.
Moradi P; Hasanzadeh A; Radmanesh F; Rajai Daryasarei S; Hosseini ES; Kiani J; Shahbazi A; Nourizadeh H; Eslami M; Dorgalaleh A; Sahlolbei M; Hamblin MR; Karimi M
Nanotechnology; 2021 Nov; 33(7):. PubMed ID: 34727527
[TBL] [Abstract][Full Text] [Related]
51. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy.
Wang L; Zheng W; Liu S; Li B; Jiang X
Chembiochem; 2019 Mar; 20(5):634-643. PubMed ID: 30393919
[TBL] [Abstract][Full Text] [Related]
52. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.
Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS
J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166
[TBL] [Abstract][Full Text] [Related]
53. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
Wan T; Ping Y
Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
[TBL] [Abstract][Full Text] [Related]
54. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
[TBL] [Abstract][Full Text] [Related]
55. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
56. Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy.
Ryu JY; Won EJ; Lee HAR; Kim JH; Hui E; Kim HP; Yoon TJ
Biomaterials; 2020 Feb; 232():119736. PubMed ID: 31901692
[TBL] [Abstract][Full Text] [Related]
57. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.
Xu X; Liu C; Wang Y; Koivisto O; Zhou J; Shu Y; Zhang H
Adv Drug Deliv Rev; 2021 Sep; 176():113891. PubMed ID: 34324887
[TBL] [Abstract][Full Text] [Related]
58. Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing.
Rohiwal SS; Dvorakova N; Klima J; Vaskovicova M; Senigl F; Slouf M; Pavlova E; Stepanek P; Babuka D; Benes H; Ellederova Z; Stieger K
Sci Rep; 2020 Mar; 10(1):4619. PubMed ID: 32165679
[TBL] [Abstract][Full Text] [Related]
59. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.
Wang D; Chen L; Li C; Long Q; Yang Q; Huang A; Tang H
J Nanobiotechnology; 2022 Jan; 20(1):27. PubMed ID: 34991617
[TBL] [Abstract][Full Text] [Related]
60. CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.
Vaghari-Tabari M; Hassanpour P; Sadeghsoltani F; Malakoti F; Alemi F; Qujeq D; Asemi Z; Yousefi B
Cell Mol Biol Lett; 2022 Jun; 27(1):49. PubMed ID: 35715750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
